Results 51 to 60 of about 888,393 (367)
‘Placebos’ and the logic of placebo comparison [PDF]
Biology & Philosophy, 2011 Robin Nunn has argued that we should stop using the terms ‘placebo’ and ‘placebo effect’. I argue in support of Nunn’s position by considering the logic of why we perform placebo comparisons. Like all comparisons, placebo comparison is just a case of comparing one thing with another, but it is a mistake, I argue, to think of placebo comparison as a ...
openaire +4 more sources
Commentary: analyzing binary data using MCPMod when zero counts are expected [PDF]
arXiv, 2022 Bretz et al (2005) proposed multiple Comparison Procedure and Modeling (MCPMod) method to design and analyze dose-finding study. Pinheiro (2014) then generalized it to various types of endpoint, including but not limited to binary endpoint, survival endpoint, count data, and longitudinal data. Pinheiro (2013) recommended to use the estimated covariance
arxiv
Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model [PDF]
Annals of Applied Statistics 2008, Vol. 2, No. 1, 386-407, 2008 Assessing immune responses to study vaccines as surrogates of protection plays a central role in vaccine clinical trials. Motivated by three ongoing or pending HIV vaccine efficacy trials, we consider such surrogate endpoint assessment in a randomized placebo-controlled trial with case-cohort sampling of immune responses and a time to event endpoint ...
arxiv +1 more source
The Scientific World Journal, 2000 Nature and Science ran completely different news line-ups this week. But their lead stories agreed on one thing: patients matter. Nature led with a story about a group of patients who will share in a patent after giving blood and tissue samples to scientists.
openaire +3 more sources
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
New England Journal of Medicine, 2016 BACKGROUND Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy.
F. Nevens +31 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression [PDF]
Multiple Sclerosis Journal, 19(12):1580-1586, 2013, 2013 Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS). Methods: We conducted a systematic literature search of RCTs in RMS.
arxiv +1 more source
Molecular Oncology, Volume 19, Issue 4, Page 1229-1243, April 2025.We assessed the associations between the gut microbiota and outcome in metastatic triple‐negative breast cancer patients treated with chemotherapy alone or chemotherapy in combination with immunotherapy. Our data indicate that high gut microbiota alpha diversity was associated with improved clinical outcome and with benefit from immunotherapy.
Andreas Ullern +8 more
wiley +1 more source
A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omiprazole in the treatment of cutaneous leishmaniasis [PDF]
Journal of Vector Borne Diseases, 2008 Background & objectives: Pentavalent antimony compounds are the first line of drugs in the treatment of cutaneous leishmaniasis. However, because of their potential toxic effects, many investigations are performed to find an effective and safe treatment ...
M.A. Nilforoushzadeh +5 more
doaj
"AI enhances our performance, I have no doubt this one will do the same": The Placebo effect is robust to negative descriptions of AI [PDF]
arXiv, 2023 Heightened AI expectations facilitate performance in human-AI interactions through placebo effects. While lowering expectations to control for placebo effects is advisable, overly negative expectations could induce nocebo effects. In a letter discrimination task, we informed participants that an AI would either increase or decrease their performance by
arxiv